<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04694365</url>
  </required_header>
  <id_info>
    <org_study_id>SHR3162-I-117</org_study_id>
    <nct_id>NCT04694365</nct_id>
  </id_info>
  <brief_title>Safety and Pharmacokinetics of Fluzoparib in Healthy Subjects and Those With Impaired Liver Function</brief_title>
  <official_title>A Open, Single-dose, Parallel-control Study to Investigate the Pharmacokinetics of Fluzoparib in Healthy Subjects and Those With Impaired Liver Function.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate the safety and pharmacokinetics of Fluzoparib in subjects&#xD;
      with impaired liver function in comparison with healthy subjects ,to develop dose&#xD;
      recommendations for patients with hepatic impairment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 6, 2020</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics parameters of Fluzoparib: Cmax</measure>
    <time_frame>through study completion, an averange of half year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics parameters of Fluzoparib: AUC0-t</measure>
    <time_frame>through study completion, an averange of half year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics parameters of Fluzoparib: AUC0-∞(if available)</measure>
    <time_frame>through study completion, an averange of half year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Other pharmacokinetics parameters of Fluzoparib: Tmax</measure>
    <time_frame>through study completion, an averange of half year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma protein binding rate of Fluzoparib</measure>
    <time_frame>through study completion, an averange of half year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence and severity of adverse events/serious adverse events (based on NCI-CTCAE 5.0)</measure>
    <time_frame>through study completion, an averange of half year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other pharmacokinetics parameters of Fluzoparib: T1/2 etc.</measure>
    <time_frame>through study completion, an averange of half year</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Hepatic Impairment</condition>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>Normal Hepatic Function</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Mild Hepatic Impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Moderate Hepatic Impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluzoparib</intervention_name>
    <description>A single oral dose of 50 mg Fluzoparib will be administered.</description>
    <arm_group_label>Mild Hepatic Impairment</arm_group_label>
    <arm_group_label>Moderate Hepatic Impairment</arm_group_label>
    <arm_group_label>Normal Hepatic Function</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for subjects with impaired liver function:&#xD;
&#xD;
          1. Sign the informed consent before the trial, and fully understand the trial content,&#xD;
             process and possible adverse reactions;&#xD;
&#xD;
          2. Ability to complete the study as required by the protocol;&#xD;
&#xD;
          3. Healthy male or female subjects aged 18 to 65 (including 18 and 45) at the date of&#xD;
             signing the informed consent;&#xD;
&#xD;
          4. Male body weight ≥ 50 kg, female body weight ≥ 45 kg, and body mass index (BMI) within&#xD;
             the range of 19 ~ 29kg /m2 (including 19 and 29);&#xD;
&#xD;
          5. Participants with alcoholic liver disease, autoimmune liver disease, Non-Alcoholic&#xD;
             Liver Diseases and inherited metabolic liver disease. Mild Hepatic Impairment group&#xD;
             should be stable≥28days ; Moderate Hepatic Impairment group should be stable≥14days.&#xD;
&#xD;
        Exclusion Criteria impaired liver function:&#xD;
&#xD;
          1. Allergic constitution;&#xD;
&#xD;
          2. History of drug use, or drug abuse screening positive;&#xD;
&#xD;
          3. Alcoholic or often drinkers;&#xD;
&#xD;
          4. Received any surgery in the previous 6 months before screen phase;&#xD;
&#xD;
          5. A clear medical history of important primary organ diseases such as nervous system,&#xD;
             cardiovascular system, urinary system, digestive system, respiratory system,&#xD;
             metabolism and musculoskeletal sysem.&#xD;
&#xD;
          6. Abnormal clinical laboratory tests and clinical significance judged by the&#xD;
             investigator or other clinical findings showing the following diseases, including but&#xD;
             not limited to gastrointestinal tract, kidney, liver, nerve, blood, endocrine, tumor,&#xD;
             lung, immune, mental or cardiovascular and cerebrovascular diseases.&#xD;
&#xD;
          7. Patients with hepatic encephalopathy;&#xD;
&#xD;
          8. Taking any drugs which affects the metabolic enzyme CYP3A within 14 days before the&#xD;
             study started,&#xD;
&#xD;
        Inclusion Criteria for subjects with normal liver function:&#xD;
&#xD;
          1. Sign the informed consent before the trial, and fully understand the trial content,&#xD;
             process and possible adverse reactions;&#xD;
&#xD;
          2. Ability to complete the study as required by the protocol;&#xD;
&#xD;
          3. Healthy male or female subjects aged 18 to 65 (including 18 and 45) at the date of&#xD;
             signing the informed consent;The age and gender should match with impaired liver&#xD;
             function;&#xD;
&#xD;
          4. Male body weight ≥ 50 kg, female body weight ≥ 45 kg, and body mass index (BMI) within&#xD;
             the range of 19 ~ 29kg /m2 (including 19 and 29); The body weight should match with&#xD;
             impaired liver function.&#xD;
&#xD;
        Exclusion Criteria normal liver function:&#xD;
&#xD;
          1. Allergic constitution;&#xD;
&#xD;
          2. History of drug use, or drug abuse screening positive;&#xD;
&#xD;
          3. Alcoholic or often drinkers;&#xD;
&#xD;
          4. Received any surgery in the previous 6 months before screen phase;&#xD;
&#xD;
          5. A clear medical history of important primary organ diseases such as nervous system,&#xD;
             cardiovascular system, urinary system, digestive system, respiratory system,&#xD;
             metabolism and musculoskeletal sysem.&#xD;
&#xD;
          6. Abnormal clinical laboratory tests and clinical significance judged by the&#xD;
             investigator or other clinical findings showing the following diseases, including but&#xD;
             not limited to gastrointestinal tract, kidney, liver, nerve, blood, endocrine, tumor,&#xD;
             lung, immune, mental or cardiovascular and cerebrovascular diseases.&#xD;
&#xD;
          7. Taking any drugs which affects the metabolic enzyme CYP3A within 14 days before the&#xD;
             study started,&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yuya Wang</last_name>
    <phone>13918749176</phone>
    <email>Wangyuya@hrglobe.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Henan Infectious Diseases Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shuang Li</last_name>
      <phone>0371-55170252</phone>
      <email>li36918@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>December 28, 2020</study_first_submitted>
  <study_first_submitted_qc>January 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 5, 2021</study_first_posted>
  <last_update_submitted>January 3, 2021</last_update_submitted>
  <last_update_submitted_qc>January 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

